DiaMedica Therapeutics : DMAC

DMAC

Stock Data

$6.18

$0.13 (2.15%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Minneapolis, Minnesota, focused on developing innovative therapies for neurological and kidney diseases. Its lead product candidate, DM199, aims to enhance renal function in patients with diabetic kidney disease, addressing significant unmet medical needs in this patient population. With a promising pipeline and a strong commitment to clinical advancement, DiaMedica is well-positioned to deliver transformative treatment options that could significantly improve patient outcomes in the biopharmaceutical landscape. The company's strategic approach underscores its potential for growth and impact in the healthcare sector.